ARCHIVES

Drugs and Targets: Blincyto granted accelerated approval in R/R ALL

This article is from The Cancer Letter archive.

Vol. 40 No. 45 | December 5, 2014

Download PDF Visit The Full Archive

Related Articles

Foundation Issues Call For Tobacco Policy Research Proposals

November 27, 1992

Without Advisor’s Input, Healy Approves Protocol For Gene Therapy

January 15, 1993

Phase III Trial of Talimogene Laherparepvec Meets Response Rate Primary Endpoint

March 29, 2013

“Harm-Reduction” Products No Proven, IOM Report Says.

March 2, 2001

NIH Emerges From Republican Revolution With Another Increase in Appropriations

October 4, 1996

Sanofi: Zaltrap Price Reflects Competing Drugs In Second-Line Metastatic Colon Cancer

November 1, 2012